Kither Biotech is a pharmaceutical product company that develops drugs to treat chronic inflammatory diseases. One of its products is a small peptide (KIT2014) developed internally for the treatment of cystic fibrosis, a disease that predominantly affects the lungs and that currently has no cure. Kither’s product portfolio also includes a molecule (CL27) that is being developed for the treatment of chronic obstructive pulmonary diseases (COPD) and allergic asthma.
Type | Private | |
Founded | 2018 | |
HQ | Torino, IT | Map |
Website | kitherbiotech.com |
Cybersecurity rating | C | More |
Founding Date | 2018 |
Kither Biotech total Funding | $6.3 m |
Kither Biotech latest funding size | $6.28 m |
Time since last funding | 2 years ago |
Kither Biotech investors | Italian Angels for Growth, Invitalia Ventures, Club degli Investitori |
When was Kither Biotech founded?
Kither Biotech was founded in 2018.
Who are Kither Biotech competitors?
Competitors of Kither Biotech include NeuClone, Teewinot Life Sciences and Fortress Biotech.
Where is Kither Biotech headquarters?
Kither Biotech headquarters is located at Via Nizza, 52, Torino.
Where are Kither Biotech offices?
Kither Biotech has an office in Torino.
How many offices does Kither Biotech have?
Kither Biotech has 1 office.
Receive alerts for 300+ data fields across thousands of companies